Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan, Gedeon Richter Unbowed By Cariprazine MDD Phase III Trial Failure

Executive Summary

Allergan and Gedeon Richter have hit a buffer in the development of their antipsychotic cariprazine in the additional indication of major depressive disorder, but they plan to proceed with a further pivotal trial, and mollified analysts with the announcement of a filing timeline to bolster the drug's label in schizophrenia.

Advertisement

Related Content

Allergan Sees Growth From New Launches, Not Big M&A

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel